Trichostatin A: Active Pharmaceutical Ingredient
Trichostatin A (TSA) was originally reported (1976) as a fungistatic antibiotic obtained from a culture broth of Streptomyces platensis. In 1987, its anti-proliferative activity was reported, and in 1990, TSA was found to cause an accumulation of acetylated histones in a variety of mammalian tumor cell lines. Subsequently, TSA’s potent inhibitory effect upon histone deacetylase activity (HDAC) was found.
Trichostatin A remains one of the most potent HDAC inhibitors available. Development of TSA as a therapeutic agent has been neglected partly due to its costly production and isolation from fermentation broth. TSA’s pharmacological activity is now found to affect both gene expression of treated tumor cells and to be a profound therapeutic agent in several non-cancer diseases.
EGT has successfully achieved a chemical synthesis of (+)-TSA (≥99% by HPLC) that provides for a cost attractive supply in larger quantities.
* * *
Trichostatin A pricing starts at $40.00 per mg and is available for immediate shipping. Large discounts available for bulk quantity orders.
*All proceeds from the sales of TSA go to Orphan Disease Research!
For more information on ordering Trichostatin A, please contact EGT at TSA@errantgene.com or (312) 441-1800.